# Quality Review — CQ #2: S′/ΔS′ Systemic Fragility in Lung Cancer

**Report reviewed:** `sprime-sl-systemic-fragility-report.md`
**KG reviewed:** `sprime-sl-systemic-fragility-knowledge-graph.json`
**Synapse grounding reviewed:** `sprime-sl-systemic-fragility-synapse-grounding.md`
**Review date:** 2026-03-15
**Pipeline:** Fuzzy-to-Fact v2
**Review context:** Publication pipeline (Stage 2) — incorporates prior `/ob-review` (9.2/10 PASS) plus Synapse grounding evaluation

---

## Summary Verdict

- **Overall: PASS (9.2 / 10)** *(unchanged from prior ob-review)*
- **Template: T1 (Drug Discovery) + T2 (Gene/Protein Network) + T6 (Mechanism Elucidation)**
- **KG Statistics:** 51 nodes · 63 edges · 19 genes · 13 compounds · 10 trials · 9 Synapse datasets · 13 nodes grounded
- **Prior review:** `/ob-review` scored 9.2/10 PASS after CDC25B and BRD4 fixes. All 10 dimensions evaluated.
- **Changes since prior review:** Stage 1b added `synapse_grounding` arrays to 13 KG nodes and `synapse_grounding_summary` metadata. No report content, evidence grades, or factual claims were modified.

---

## Dimension Scores

| # | Dimension | Score | Notes |
|---|-----------|-------|-------|
| 1 | CURIE Resolution | **PASS** | Unchanged. 18/18 genes HGNC-resolved, 10/12 compounds ChEMBL-resolved, 1 disease MONDO, 10 trials NCT-verified. |
| 2 | Source Attribution | **PASS** | Unchanged. 103 source citations. Synapse grounding document adds `search_synapse` citations for 9 datasets. |
| 3 | LOCATE → RETRIEVE | **PASS** | Unchanged. Two-step resolution pattern documented for all entity types. |
| 4 | Disease CURIE | **PASS** | Unchanged. MONDO:0008903 present in KG and report. |
| 5 | OT Pagination | **N/A** | Unchanged. No `knownDrugs` endpoint used. |
| 6 | Evidence Grading | **PASS** | Unchanged. 19 claims with L1-L4 grades and numeric scores (0.45-0.92). Median 0.72. |
| 7 | GoF Filter | **N/A** | Unchanged. All architectures are loss-of-function. |
| 8 | Trial Validation | **PASS** | Unchanged. 10/10 NCT IDs verified. |
| 9 | Completeness | **PASS** | Unchanged from post-fix assessment. Synapse grounding adds dataset coverage for all 4 architectures. |
| 10 | Hallucination Risk | **LOW** | Unchanged. No fabricated entities, no unsourced claims. Synapse IDs are valid (syn274449, syn274452, syn17084070, etc.). |

---

## Synapse Grounding Evaluation (New for Publication Pipeline)

### Grounding Quality Assessment

| Criterion | Assessment |
|-----------|------------|
| Compound queries used | **Yes** — 7 multi-term queries (e.g., "PTEN lung cancer synthetic lethality", "CDKN2A MTAP PRMT5 lung cancer") |
| Strength classification applied | **Yes** — 4-tier: Strong (1), Moderate (3), Analogous (4), Weak (1) |
| Coverage per architecture | **Complete** — all 4 architectures have ≥1 grounding dataset |
| Disease-match specificity | **Partial** — strongest grounding (TCGA LUAD/LUSC) matches NSCLC; PRMT5, DDR, and SL methodology datasets are from NF1/leukemia/ovarian contexts |
| KG injection | **Complete** — `synapse_grounding` arrays added to 13 nodes; metadata summary added |

### Grounding Strength Distribution

| Strength | Count | Assessment |
|----------|-------|------------|
| Strong | 1 | TCGA LUAD — directly profiles all 4 TSGs in NSCLC. Appropriate classification. |
| Moderate | 3 | TCGA LUSC, SCLC systems biology, Spatial LUAD. All relevant to NSCLC or SCLC. Appropriate. |
| Analogous | 4 | Same molecular mechanisms in different diseases (NF1, leukemia, ovarian). Correctly classified as analogous rather than moderate. |
| Weak | 1 | Anti-PD1 DREAM challenge uses AURKA/PLK1/CHEK1 as biomarkers but doesn't test SL. Appropriate. |

### Grounding Gaps

- **No direct SL screening dataset in NSCLC on Synapse.** This is a genuine coverage gap — Synapse's strongest SL data is in the NF1 domain. The grounding document correctly identifies this limitation.
- **PRMT5/MTAP grounding is disease-mismatched.** syn64500888 tests the same mechanism in NF1 glioma. Classified as "analogous" — appropriate.
- **DepMap/CRISPR essentiality data not on Synapse.** BioGRID ORCS returned null metadata during pipeline execution. DepMap data (which would provide genotype-stratified essentiality) is hosted on Broad/DepMap portal, not Synapse. Documented gap.

### Synapse Verdict: ACCEPTABLE

The grounding achieves the expected coverage level for a lung cancer CQ on Synapse. The document correctly identifies that Synapse has "moderate coverage" for lung cancer genomics and that the strongest support comes from TCGA. No overclaiming of grounding strength.

---

## Changes from Prior Review

| Item | Prior Review | Current | Change |
|------|-------------|---------|--------|
| KG metadata | No synapse fields | `synapse_grounding_summary` added | New metadata block |
| Node structure | No `synapse_grounding` arrays | 13/51 nodes have grounding arrays | Structural addition |
| Report content | 411 lines, 103 citations | Unchanged | No modification |
| Evidence grades | 19 claims, median 0.72 | Unchanged | No modification |
| New files | 3 files (report, KG, quality review) | 5 files (+synapse grounding, updated quality review) | Publication pipeline output |

---

## Failure Classification

**No new failures identified.** All prior PARTIAL items remain resolved. Synapse grounding is ACCEPTABLE.

| # | Dimension | Score | Status |
|---|-----------|-------|--------|
| 1-4, 6, 8-10 | All applicable dimensions | PASS | ✅ |
| 5, 7 | N/A dimensions | N/A | — |
| Synapse | Grounding quality | ACCEPTABLE | ✅ |

---

## Overall Assessment

**Protocol execution: 9.0 / 10** (unchanged)
**Report presentation: 8.5 / 10** (unchanged)
**Synapse grounding: 7.5 / 10** (new — reflects partial disease-match coverage, appropriate for lung cancer domain on Synapse)
**Publication readiness: PASS**

The report, KG, and Synapse grounding are ready for Stage 3 (BioRxiv draft). The core scientific claims, evidence grades, and source citations are unchanged from the prior PASS review. The Synapse grounding adds dataset-level support for 4/4 genotype architectures, with appropriate strength classifications and honest gap documentation.

### Comparison to CQ #1

| Metric | CQ #1 | CQ #2 |
|--------|-------|-------|
| Overall score | 8.5 (PARTIAL) | 9.2 (PASS) |
| Dimensions at PASS | 6/8 applicable | 8/8 applicable |
| Evidence grading | 14 claims, L1-L4 | 19 claims, L1-L4 |
| Negative results | None documented | NCT02688907 (0% ORR) integrated |
| Synapse grounding | Not yet performed | 9 datasets, 13 nodes grounded |
| Publication readiness | Pending fixes | PASS |

---

*Quality review performed for publication pipeline Stage 2. Prior `/ob-review` (9.2/10 PASS) confirmed. Synapse grounding evaluated. All 5 publication files verified structurally consistent.*
